Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

129.83 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

54 55 Next >

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong. ↗

July 12, 2026

Gilead's expansion beyond HIV therapies will surprise many investors.

Via The Motley Fool

Topics Intellectual Property

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗

July 11, 2026

IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.

Via The Motley Fool

Topics ETFs

Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗

July 11, 2026

BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.

Via The Motley Fool

Topics ETFs

Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector ↗

June 29, 2026

Via Chartmill

What's going on in today's session: S&P500 movers ↗

July 10, 2026

Via Chartmill

2 Recession-Resistant Dividend Stocks to Buy and Hold ↗

July 10, 2026

You don't need to predict a recession to prepare your portfolio. These two stocks can help.

Via The Motley Fool

Topics Economy

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗

July 10, 2026

Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? ↗

July 08, 2026

IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility.

Via The Motley Fool

Topics ETFs

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? ↗

July 08, 2026

Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry.

Via The Motley Fool

Topics ETFs

Stay informed with the top movers within the S&P500 index on Tuesday. ↗

July 07, 2026

Via Chartmill

Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says ↗

July 06, 2026

HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential.

Via Benzinga

FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗

July 04, 2026

Compare fees, diversification, and risk between these two leading healthcare ETFs.

Via The Motley Fool

Topics ETFs

If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗

July 03, 2026

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market...

Via Benzinga

SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗

July 02, 2026

Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs.

Via The Motley Fool

Topics ETFs

Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer ↗

June 25, 2026

FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda.

Via Benzinga

This ETF Has More Than Doubled the S&P 500's Returns Over the Past Decade. Is It a Buy for the Next Decade? ↗

June 25, 2026

It may not duplicate those impressive results, but it has all the tools it needs.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗

June 23, 2026

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

Via MarketBeat

Topics ETFs

3 S&P 500 Stocks with Exciting Potential

June 23, 2026

The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innova...

Via StockStory

Topics Stocks

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?

June 18, 2026

Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short o...

Via StockStory

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

June 17, 2026

Via Benzinga

1 Cash-Producing Stock Worth Investigating and 2 We Brush Off

June 17, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial ↗

June 09, 2026

Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends

Via Benzinga

Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead ↗

June 08, 2026

Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming...

Via MarketBeat

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands ↗

June 05, 2026

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease...

Via MarketBeat

Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗

June 04, 2026

Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.

Via The Motley Fool

Topics ETFs

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome ↗

June 02, 2026

Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks.

Via Benzinga

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

June 01, 2026

Via Benzinga

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗

May 29, 2026

This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.

Via The Motley Fool

If You Invested $1000 In Gilead Sciences Stock 15 Years Ago, You Would Have This Much Today ↗

May 26, 2026

Via Benzinga

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference ↗

May 24, 2026

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC...

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9

...

54 55 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.